How many 8-K filings has Vincerx Pharma, Inc. filed?

Vincerx Pharma, Inc. (VINC) has 20 8-K (Current Event Report) filings on record, spanning Jan 2024 to Jul 2025.

What is a 8-K filing?

A 8-K is an SEC filing known as "Current Event Report." Filed to announce significant events or material changes such as acquisitions, executive departures, earnings announcements, or bankruptcy filings.

Where can I read Vincerx Pharma, Inc. 8-K filings in plain English?

ReadTheFiling provides AI-powered plain-English summaries of all Vincerx Pharma, Inc. 8-K filings, including risk assessment, sentiment analysis, and key financial figures.

Vincerx Pharma, Inc. (VINC) — 8-K Filings

All 8-K filings from Vincerx Pharma, Inc.. Browse 20 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (20)

Vincerx Pharma Announces Executive Changes and Agreement Termination — Jul 7, 2025 Risk: medium
On June 30, 2025, Vincerx Pharma, Inc. announced the termination of a material definitive agreement. The company also reported the departure of certain officers
Vincerx Pharma Faces Delisting Concerns — Apr 17, 2025 Risk: high
Vincerx Pharma, Inc. filed an 8-K on April 17, 2025, reporting a notice of delisting or failure to satisfy continued listing rules. The company was formerly kno
Vincerx Pharma Terminates Material Definitive Agreement — Apr 11, 2025 Risk: medium
Vincerx Pharma, Inc. announced on April 7, 2025, the termination of a material definitive agreement. The company, formerly known as LifeSci Acquisition Corp. an
Vincerx Pharma Enters Material Definitive Agreement — Mar 18, 2025 Risk: medium
On March 14, 2025, Vincerx Pharma, Inc. entered into a Material Definitive Agreement. The company, formerly known as LifeSci Acquisition Corp. and Vincera Pharm
Vincerx Pharma Terminates Material Definitive Agreement — Feb 28, 2025 Risk: medium
Vincerx Pharma, Inc. announced on February 25, 2025, the termination of a material definitive agreement. The company, formerly known as LifeSci Acquisition Corp
Vincerx Pharma to be Acquired by LifeSci Acquisition Corp. — Feb 18, 2025 Risk: medium
Vincerx Pharma, Inc. announced on February 11, 2025, that it entered into a definitive agreement to be acquired by a subsidiary of LifeSci Acquisition Corp. The
Vincerx Pharma Files 8-K, Reports Material Agreement — Feb 6, 2025 Risk: medium
Vincerx Pharma, Inc. filed an 8-K on February 6, 2025, reporting a material definitive agreement as of January 31, 2025. The filing also includes financial stat
Vincerx Pharma Files 8-K — Jan 23, 2025 Risk: low
On January 23, 2025, Vincerx Pharma, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits. The company was for
Vincerx Pharma Files 8-K: Material Agreement, Other Events — Jan 21, 2025 Risk: medium
On January 21, 2025, Vincerx Pharma, Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes other events and financial sta
Vincerx Pharma Terminates Material Agreement — Jan 16, 2025 Risk: medium
Vincerx Pharma, Inc. announced on January 10, 2025, the termination of a material definitive agreement. The company also submitted matters to a vote of its secu
Vincerx Pharma CMO Departs, Interim Appointed — Dec 27, 2024 Risk: medium
On December 20, 2024, Vincerx Pharma, Inc. announced the departure of Dr. Michael R. Bristow from his role as Chief Medical Officer. The company also appointed
Vincerx Pharma Files 8-K on Exit Costs and Other Events — Dec 6, 2024 Risk: medium
Vincerx Pharma, Inc. filed an 8-K on December 6, 2024, reporting on cost associated with exit or disposal activities and other events. The filing also includes
Vincerx Pharma Faces Delisting Concerns — Nov 25, 2024 Risk: high
Vincerx Pharma, Inc. filed an 8-K on November 25, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company, previously
Vincerx Pharma Files 8-K — Oct 7, 2024 Risk: low
Vincerx Pharma, Inc. filed an 8-K on October 7, 2024, to report other events. The filing does not contain specific details about the nature of these events, but
Vincerx Pharma Appoints New CMO, CEO Compensation Update — Aug 16, 2024 Risk: medium
On August 12, 2024, Vincerx Pharma, Inc. announced changes in its board of directors and executive compensation. Specifically, Dr. Michael J. Ybarra was appoint
Vincerx Pharma Faces Delisting Concerns, Files 8-K — May 28, 2024 Risk: high
Vincerx Pharma, Inc. filed an 8-K on May 28, 2024, reporting events as of May 22, 2024. The filing indicates a notice of delisting or failure to meet continued
Vincerx Pharma Files 8-K — Apr 26, 2024 Risk: low
Vincerx Pharma, Inc. filed an 8-K on April 26, 2024, reporting other events and financial statements. The company, formerly known as LifeSci Acquisition Corp. a
Vincerx Pharma Files 8-K on Financials — Apr 25, 2024 Risk: low
On April 25, 2024, Vincerx Pharma, Inc. filed an 8-K report detailing its financial condition and other events. The company, formerly known as LifeSci Acquisiti
Vincerx Pharma Files 8-K: Other Event Reported — Apr 8, 2024 Risk: low
On April 8, 2024, Vincerx Pharma, Inc. filed an 8-K report detailing an "Other Event." The filing does not contain specific financial figures or new material in
Vincerx Pharma Files 8-K on Jan 12 Event; Confirms Nasdaq Listing — Jan 16, 2024
Vincerx Pharma, Inc. filed an 8-K on January 16, 2024, reporting an 'Other Event' that occurred on January 12, 2024. This filing primarily updates administrativ

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX